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ABSTRACT
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a positive singlestranded ribonucleic acid (ssRNA) virus in the Coronavridae family that was first identified in December 2019. The virus causes a disease named COVID-19, which is associated with various respiratory symptoms ranging from mild to life-threatening complications. The pandemic state was
announced by the World Health Organization (WHO) in March 2020. Since then, the viral genome
and structure have been extensively studied. This review aims to present the most recent advances
in the SARS-CoV-2. The viral genome encodes 16 non-structural proteins involved in viral replication and transcription, four structural proteins assembled to form the virions, and at least six accessory proteins involved in viral pathogenicity and virions assembly. Being an RNA virus, the SARSCoV-2 genome undergoes rapid mutations. Several thousand mutations in the submitted genomes
compared with the first strain have been reported since the pandemic's beginning. Some mutations
such as the ''Cluster 5'' variant, VOC 202012/01, and the N501Y mutation raised public health concerns globally because they could affect the virus transmissibility, disease severity, diagnostic
methods, and vaccine development. The virus infects humans by recognizing the ACE2 receptor on
the human cells and the TMPRSS2 proteolytic effect. The gold standard diagnostic method based
on the WHO is nucleic acid amplification testing; however, several other non-molecular and radiological testing could also be beneficial. Several trials have been initiated to produce an effective
vaccine, more than 60 have reached clinical trials, and some have recently been approved. The
leading vaccines are the RNA-based ones; BNT162b2 and Moderna. Further studies are required to
evaluate the vaccines' effectiveness, diagnostic efficacy, and disease management to keep pace with
the ongoing viral evolution.
Keywords: SARS-CoV-2, ACE2, vaccine, TMPRSS2.
East respiratory syndrome coronavirus
INTRODUCTION
(MERS-CoV), first identified in Saudi Arabia
The Coronaviridae family of viruses is a
and caused an outbreak in 2012 (5).
large group of forty-six species enveloped in
In 2019, several cases of pneumonia
single-stranded RNA viruses with crown-like
with unknown etiology were recognized for
viral particles (1). These viruses infect many
the first time in China (6). The etiological
species, including humans, birds, and wild or
agent was then identified as the seventh spedomestic mammals. Since the 1960s, six species of Coronaviridae viruses known to incies in this family have been known to infect
fect humans, and it was named SARS-CoVhumans. Four of them are associated with
2. The nomenclature relies on the genetic
mild diseases in the respiratory and gastroinanalysis that revealed a high similarity of the
testinal tracts and are designated as human
novel virus with the SARS-CoV virus, which
coronavirus HKU1 (HCoV-HKU1), HCoVcaused the pandemic in 2003, even though
NL63, HCoV-OC43, and HCoV-229E (2, 3).
the two viruses vary in function and pathoThe other two species caused severe public
genicity (7, 8). The number of SARS-CoV-2
health concerns in the twenty-first century.
cases increased drastically worldwide, and on
The first is the severe acute respiratory synMarch 11, 2020, the World Health Organizadrome coronavirus (SARS-CoV), which
tion (WHO) announced a global pandemic
caused the epidemic outbreak in Guangdong,
state due to the novel coronavirus (SARSChina, in 2003 (4). The second is the Middle
CoV-2) (9, 10). Nowadays, the SARS-CoV-2

218 “ ــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــThe molecular basis of the severe acute respiratory ……”

is affecting more than 200 countries, and the
number of cases increased globally from less
than a hundred thousand in February 2020 to
more than 200 million on September 14,
2021, according to the American Library Association certified Worldometer (11).
Sars-cov-2 genome
Based on the classification of the International Committee on Taxonomy of Viruses
(ICTV), the novel severe acute respiratory
syndrome-related coronavirus (SARS-CoV2) is a species in the Sarbecovirus subgenus
in the genus of Betacoronavirus within the
Coronaviridae family of viruses in the order
of Nidovirales (1).
Generally, the coronavirus's genome is
considered the largest among all RNA viruses, typically ranging from 27000 to 32000
bases (12, 13). For the SARS-CoV-2, it is
around 29000 bases (7). At the whole genome level, it is annotated that the novel viral
genome has 79% shared sequence identity
with SARS-CoV (14) and 50 % with MERSCoV (15). The genome is even more similar
to two SARS-like bat CoVs with a shared
sequence identity of 87.99% with the bat-SLCoVZC45 and 87.23% with the bat-SLCoVZXC2 (15).
Mutations that contribute to the viral
evolution occur continuously in viruses, with
higher rates observed in RNA viruses than in
DNA viruses (16). These mutations usually
aid the virus in evading the host immune defense and vaccine-induced immunity; however, some mutations are deleterious and may
be associated with viral extinction (17). The
mutation rate is variable among viruses, and
it is not just influenced by polymerase fidelity but also by genomic architecture and replication speed (16). Generally, RNA viruses
exhibit a high mutation rate attributed mainly
to the lack of proofreading activity in their
RNA polymerase, but the polymerases of the
Coronaviruses and other viruses in the
Nidovirales family have the proofreading
mechanism (18). Moreover, a higher muta-

tion rate is observed in viruses with a singlestranded genome than in double-stranded
ones and viruses with small genome size
(19). As a result, an amassed number of genomic variations in the SARS-CoV-2 complete genome 66 000 complete viral genomic
sequences of SARS-CoV-2 have been submitted up to July 2020 (20). While the viral
infectivity, transmission, protein structures,
diagnostic accuracy, and drug effectivity
might be influenced to benefit either the virus
or the host, the mutation could also be neutral
(21).
genes and proteins
The SARS-CoV-2 genome is distinguished by the presence of a 5' cap and a 30
poly(A) tail, as well as multiple open reading
frames (ORF), encoding several structural
and non-structural proteins, with 58% shared
identity among coronavirus species (7, 22).
Six main ORFs are shared within coronaviruses and several accessory proteins (23).
The first two-thirds at the 5' end of the genome contain two open reading frames
(ORF1a and ORF1b) encoding for two polyproteins (pp1a and pp1ab). These polyproteins are enzymatically cleaved by virally
encoded proteinases into 16 non-structural
proteins (Nsp) that are highly preserved
among various coronaviruses, and they form
the replication-transcription complex (22, 24)
(Table 1). At the same time, the last third of
the genome confers four structural viral proteins, including the spike (S), membrane (M),
envelope (E), and nucleocapsid (N) proteins
(25) (Figure 1). Besides, the last third of the
genome encodes many accessory proteins
distributed between the structural ones. These
proteins are involved in viral virulence and
pathogenicity (7, 26, 27). At least 6 accessory
proteins have been identified in SARS-CoV2
(3a, 6, 7a, 7b, 8, and 10) (7, 28, 29). However, it is believed that SARS-CoV-2 accessory
proteins are six to nine proteins (30-32) (Table 2) (Figure 2).
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Table (1): SARS-CoV-2 non-structural proteins.
Gene

Protein

Function

Nsp1

Leader Protein

Inhibits the expression of the host genes via binding
host cells 40S ribosome and induces degradation of
host mRNA
Binds to prohibitin one and 2 (PHB1 and PHB2) have
vital roles in cell cycle progression and signaling
pathways.
PLpro is produced through autocleavage, releasing the
nsp1, nsp2, and nsp3.
It inhibits the host immune response by deubiquitinating and deISGylating functions.
A transmembrane protein responsible for membranes
rearrangement and double membranes vesicles formation
The main protease (also named M pro). Responsible for
polyproteins processing and inhibiting type one interferons signaling pathway.
Viral pathogenesis, Disrupt lysosomal degradation of
the virus by limiting autophagosome expansion
Viral replication: it forms a heterodimer with nsp8 and
acts as a cofactor for nsp12 (RdRp) to form the RNA
polymerase complex
Viral replication: it forms a heterodimer with nsp7, and
a monomer of nsp8 works as a cofactor for nsp12
(RdRp) to form the RNA polymerase complex
It is required for viral replication; the nsp9 dimerizes to
enhance its RNA binding for replication.
It interacts with nsp14 and nsp16 and stimulates their
enzymatic activity.
Unknown function
It forms the catalytic subunit with RNA-dependent
RNA polymerase (RdRp) activity and requires nsp7
and nsp8 for optimal polymerase efficiency.
Unwinds the duplex RNA and possesses 5′triphosphatase activity
Promotes RNA polymerase fidelity via its 3'-5' exoribonuclease activity, and its guanine N7methyltransferase role introduces the 5′-cap of the virus RNA cap, which is vital for translation and evading
host defense via
Manganese endoribonuclease activity which targets the
viral polyuridine sequences is used for evading host
sensing of viral dsRNA
Important for host immune system evasion: methylate
the 2′-hydroxy group of adenine to form the 5' cap of
the virus, which protects the viral mRNA degradation

Nsp2

Nsp3

Papain like Proteinase (PLpro)

Nsp4

Nsp5

3C-like proteinase

Nsp6
Nsp7

Nsp8

Nsp9
Nsp10
Nsp11
Nsp12

RNA Dependent
RNA Polymerase

Nsp13

Helicase

Nsp14

3′ to 5′ Endonuclease,
N7-Methyltransfer
ase

Nsp15

endoRNAse

Nsp16

2′-O-Ribose-Meth
yltransferase

Reference
(33)

(29)

(29, 34)

(35, 36)

(37, 38)

(39, 40)
(41)

(41)

(42, 43)
(44, 45)
(29)
(41)

(46)
(47)

(48)

(49)
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Table (2): SARS-CoV-2 open reading frames.
Gene
ORF1a

Protein
pp1a

ORF1b

pp1ab

ORF2
(S)

Spike protein

ORF3a

Accessory protein (3a)
Envelope protein

ORF4
(E)
ORF5
(M)
ORF6
ORF7a
ORF7b

ORF8
ORF9
(N)
ORF10

Membrane protein
Accessory protein
Accessory protein
Accessory protein
Accessory protein
Nucleocapsid
protein
Accessory protein

Function
Proteolytically cleaved by two cysteine proteases, 3Clike proteinase, and PLpro into several non-structural
proteins (nsp1-11)
Proteolytically cleaved by two cysteine proteases, 3Clike proteinase, and PLpro into several non-structural
proteins (nsp1-10 and nsp12-16)
S1 subunit is used for viral attachment to the host receptor ACE2.
The S2 subunit is responsible for fusing the viral and
cell membranes.
Apoptosis induction in host cells

Reference
(50, 51)

It is involved in viral assembly, envelope formation,
viral budding, and ion channel activity.
It provides a scaffold in viral assembly and mediates
inflammatory responses in hosts.
It suppresses the host antiviral immune response mediated by the type I interferon signaling pathway
Involved in the activation of pro-inflammatory cytokines and chemokines, such as IL-8.
It acts as an accessory and structural protein that localize in the Golgi compartment and is also incorporated
into viral particles
Suppress the host antiviral immune response mediated
by the interferon (type I) signaling pathway.
Aids in the host cell entry and interaction with cellular
processes via binding to the viral RNA to form a core
of a ribonucleoprotein
Interacts with Cullin-ubiquitin-ligase complex and
controls the host-ubiquitin machinery for viral pathogenesis

(53)

(50, 51)

(7)

(52)

(54)
(55)
(56)
(29, 57)

(55)
(54)

(58)
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Figure (1): SARS-CoV-2 structure (Created with BioRender.com).
)(N) proteins (Created with BioRender.com
(59).

The virus contains four structural proteins, which are the spike (S), the envelope
(E), the membrane (M), and the nucleocapsid

Figure (2): SARS-CoV-2 genome organization (Created with BioRender.com).
 Palestinian Medical and Pharmaceutical Journal (PMPJ). 2022; 7(2): 217-236ــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ

222 “ ــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــThe molecular basis of the severe acute respiratory ……”

ease Control and Prevention (CDC) and the
WHO, these variants are B.1.1.7 (Alpha),
B.1.351 (Beta), B.1.617.2 (Delta), and P.1
(Gamma) variants shown in table 3. The alpha, the most common observed variant in
December 2019, is associated with increased
viral infectivity and transmission with no impact on the disease severity (65-68).

The genome contains two open reading
frames (ORF1a and ORF1b) encoding for
two polyproteins (pp1a and pp1ab) which are
enzymatically cleaved into 16 non-structural
proteins (Nsp). The genome encodes four
structural proteins: S, E, M, and N, and at
least 6 accessory proteins, namely include;
3a, 6,7a,7b, 8, and 10 (Created with BioRender.com) (60).

Another SARS-CoV-2 variant of minks
raised a new concern in August and September 2020. This variant, which was first identified in Denmark, is characterized by four mutations, one deletion, and three substitutions
(Y453F, del69_70, I692V, and M1229I) in
the spike protein, and it has been referred to
as the "Cluster 5" variant (69, 70). Based on
preliminary studies, this spike protein variant
weakens the mutated virus's neutralization by
antibodies isolated from the previous strain
(71). The mutations in the spike protein that
enable the virus to adapt to a new host could
render the vaccine and the diagnosis strategies useless (69, 72). Fortunately, cluster 5
seems to be extinct (73).

MUTATIONS
Mutations are considered a part of all viruses' virulence mechanisms, and SARSCoV-2 is no exception. The mutation rate
ranges from 10−8 to10−6 substitutions per nucleotide site per cell infection (s/n/c) for
DNA viruses and from 10−6 to 10−4 s/n/c for
RNA viruses (61). Even after the initial cases
of SARS-CoV-2 were declared in China,
several variants in the SARS-CoV-2 genome
have been annotated. In the analysis of more
than 30000 SARS-CoV-2 submitted genomes
from 79 countries to the global initiative on
sharing avian influenza data (GISAID) database in the first five months of the epidemic,
an overall of 3206 variant sites were revealed
compared with the earliest identified WuhanHu-1/2019 reference genome (62, 63). The
entire genome is prone to mutations; however, mutations are more recurrent in S,
ORF1ab, N, ORF8, and ORF3a. On the other
hand, the E, M, ORF6, ORF7a, and ORF10
genes
are
more
conserved
across
genomes(64). Some variants are considered
of concern since they increase disease transmissibility and severity and reduce vaccines'
effectiveness or diagnostic testing. According
to the latest update from the Centers for Dis-

The most recent variant of concern is the
Omicron variant (B.1.1.529) which the WHO
reported in November 2021(74). This variant
is highly mutated compared with previous
variants, the mutations involve structural and
non-structural proteins, and around 30 mutations are just in the spike protein. Eventually,
Omicron is highly contagious, and immune
escape and reinfection are more profound
than in previous variants (75).
(see updates at
https://www.gisaid.org/hcov19-variants/):

Table (3): SARS -CoV-2 variants of concern (VOC).
WHO
variant
label
Alpha

Pango
Lineage
B.1.1.7

Country
of the
first identification
Southeast
England

Date of
designation
December
2020

Defining mutations
aa:orf1ab:T1001I
aa:orf1ab:A1708D
aa:orf1ab:I2230T
del:11288:9
del:21765:6
del:21991:3
aa:S: N501Y*
aa:S: A570D

Attributes

References

Increased
(76-81)
transmissibility, higher
viral reproduction
number
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WHO
variant
label

Pango
Lineage

Country
of the
first identification

Date of
designation

Defining mutations

Attributes

References

aa:S: P681H*
aa:S: T716I
aa:S: S982A
aa:S: D1118H
aa: Orf8:Q27
aa: Orf8:R52I
aa: Orf8:Y73C
aa:N: D3L
aa:N: S235F
Beta

B.1.351

South Africa

December
2020

aa:E: P71L
aa:N: T205I
aa:orf1a:K1655N
aa:S: D80A
aa:S: D215G
aa:S: K417N*
aa:S: A701V
aa:S: N501Y*
aa:S:E484K*

Increased
(80-83)
transmissibility

Gamma

P.1

Brazil

January
2021

aa:orf1ab:S1188L
aa:orf1ab:K1795Q
del:11288:9
aa:S: L18F
aa:S:T20N
aa:S:P26S
aa:S:D138Y
aa:S:R190S
aa:S:K417T*
aa:S:E484K*
aa:S:N501Y*
aa:S:H655Y
aa:S:T1027I
aa:orf3a:G174C
aa:orf8:E92K
aa:N:P80R

Increased
(80, 84,
transmissibil- 85)
ity

Delta

B.1.617.2

India

May 2021

S:T19R
S:L452R*
S:T478K*
S:P681R
S:D950N
ORF3a:S26L
M:I82T
ORF7a:V82A
ORF7a:T120I
N:D63G
N:R203M
N:D377Y

Higher rate
of transmissibility. more
disease severity and
rate of hospitalization

(80, 86)

Omicron

B.1.1.529

Botswana/
South Af-

November
2021

In S1 and S2:
A67V, T95I,

Higher rates
of transmis-

(74, 87)
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WHO
variant
label

Pango
Lineage

Country
of the
first identification
rica

Date of
designation

Defining mutations
G142D, G339D,
S371L, S373P,
S375F, K417N,
N440K, G446S,
S477N, T478K,
E484A, Q493K,
G496S, Q498R,
N501Y, Y505H,
T547K, D614G,
H655Y, N679K,
P681H, N764K,
D796Y, N856K,
Q954H, N969K,
L981F

Attributes

References

sibility, immune escape,
and reinfection.

* biologically significant mutations
Pathogenicity and the viral life cycle
Viral infectivity and pathogenesis are determined based on the viral entry mechanism
into the host cells. The SARS-CoV-2 attachment to the host cell is mediated by the S
protein, which recognizes the human angiotensin-converting enzyme 2 (ACE2) protein
on the host cell surface, the same receptor
that has been identified for the previous
SARS-CoV, and the reported 75% homology
supports this at the receptor-binding domain
of the spike protein between the two SARS
viruses (88-90). The S protein comprises two
functional domains (S1 and S2); the S protein
comprises two functional domains (S1 and
S2). The S1 domain, which is exposed to the
outside world, contains the receptor-binding
domain (RBD), which recognizes the ACE2
receptor on host cells (55). The transmembrane S2 domain promotes cellular-viral fusion. The fusion process requires proteasemediated structural conformation in the S
protein to facilitate viral entry into the host
cells. This proteolytic cleavage is mediated
by the cell surface transmembrane protease
serine 2 (TMPRSS2) (91). Cell-viral fusion is
followed by the viral genome released into
the host cell cytoplasm. Initially, ORF1a and
ORF1b are translated by the host ribosomes
and proteolytically cleaved into the viral nonstructural proteins that form the viral replication-transcription complex (92). Following
the replication and transcription of the viral

genome, the structural proteins are translated
into the endoplasmic reticulum membranes
before the viral particles are finally assembled and released from the host cells (93).
The structural proteins include the membrane (M) protein, an integral membrane protein, the most abundant protein on the viral
surface that aids in viral assembly (94). The
envelope (E) protein is a small transmembrane protein and a minor component of the
viral particle responsible for ion channel activity (95). The nucleocapsid (N) protein is
required for viral RNA packaging and particle release (96). Even though the S protein is
a leading target in vaccine development to
eradicate SARS-CoV-2, the N protein is
more conserved and shows a lower mutation
rate over the disease progression (97).
Hence, the cellular tropism of ACE2 and
TMPRSS2 in humans is a determinant factor
of viral pathogenesis. They coexist in the
lung pneumocytes (type II), nasal goblet
cells, and ileal absorptive enterocytes, and
that explains the pulmonary and gastrointestinal clinical features among SARS-CoV-2
cases (98) (Figure 3).
The symptoms range from mild respiratory tract infections to severe pneumonia and,
less frequently, life-threatening complications. Fever, cough, and dyspnea are the most
commonly observed characteristic symptoms
of COVID-19 (99).
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However, it is proposed that the virus
could affect multiple other organs since the
receptor is widely expressed in other human
cells, including cardiomyocytes, heart peri-

cytes, gut enterocytes, olfactory sustentacular
cells, corneal epithelial cells, and renal epithelial cells (6).

Figure (3): SARS-CoV-2 entry into host cells (Created with BioRender.com).
The virus recognizes and binds the
ACE2 receptor on the host cells; the
TMPRSS2 protease on host cells cleaves the
spike protein and mediates cellular-viral fusion. Following endocytosis, the viral genome is released into the cell cytoplasm to be
translated into the viral proteins, assembled
using the host machinery to produce more
viruses. (ACE2: angiotensin-converting enzyme 2, TMPRSS2: transmembrane protease
serine 2 (Created with BioRender.com)
(100).
IDENTIFICATION
Proper diagnosis of the novel virus is a
challenging goal worldwide to achieve the
highest diagnostic sensitivity and specificity.
Several methods and variable targets have
been deployed. The most commonly used
methods depend on directly identifying the
viral components in respiratory samples or
indirectly detecting the humoral immunity
material in blood. The diagnostic protocols

are classified into molecular and nonmolecular methods; the former has been
adopted globally as the gold standard diagnostic protocol for SARS-CoV-2 due to the
reliability of the results, even though the sensitivity and specificity are not 100%.
Molecular methods
Based on the World Health Organization's interim guidance on September 11,
2020, detecting distinctive viral sequences by
nucleic acid amplification tests (NAATs) is
the reference diagnostic method for acute
SARS-CoV-2 infections, such as real-time
reverse-transcription polymerase chain reaction (qRT-PCR). Four regions of the SARSCoV-2 genome have been targeted, including
regions of the E, N, RdRP, and S genes
(101). Even though testing two targets on the
SARS-CoV-2 genome provides optimal diagnosis, testing a single discriminatory target
in areas where SARS-CoV-2 is widespread
might be adopted. However, checking for
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mutations that might affect test performance
is recommended routinely. This mainly relies
on the fact that RNA-dependent RNA polymerases (RdRp) do not have proofreading
activity, along with the observed high mutation rate known for RNA viruses, which may
affect the primers' targeted genes, leading to
false-negative results. So, routine checking of
samples using two different sets of primers
that target distinctive genomic regions may
overcome the risk of mutations (18, 101).
The NAAT's high analytic sensitivity and
specificity are reported in an ideal diagnostic
setting. However, the test performance depends on several factors, including the duration of illness, the specific clinical features,
the type and quality of the specimen, and the
viral load. Consequently, false-negative rates
have been reported in nearly 30% of patients,
and false-positive results have also been reported in some studies (102, 103).
Even though the NAAT is currently the
recommended and most reliable diagnostic
method, access to this test is challenging in
some areas due to the demanding time, costs,
and required professional skills.
Genome sequencing is a powerful molecular technique to monitor viral evolution
and disease spread. SARS-CoV-2 genome
sequences are commonly submitted to the
GISAID database (104). The rapid evolution
of SARS-CoV-2 is a devastating challenge to
molecular diagnostic methods. An analysis of
more than 1800 viral genomes submitted to
GISAID revealed that 79% of the primer
binding sites used in qRT-PCR were mutated
in at least one genome (105). As a result, ongoing optimization of available oligonucleotides used in molecular diagnostic techniques
based on analysis of the updated genomic
sequences shared by the GISAID is a critical
requirement for maintaining high diagnostic
accuracy and pandemic control (106, 107).
Non-molecular methods
Several manufacturers developed nonmolecular diagnostic tests to directly detect
the SARS-CoV-2 proteins produced by the
replicating virus in respiratory samples,
which are considered part of the rapid diagnostic testing (RDT) strategies. Due to its
abundance in samples, antigen detection by
the RDT most commonly targets the nucle-

ocapsid protein. The test principle is based on
the simple sandwich enzyme-linked immunosorbent assay (ELISA), through which a specific conjugated antibody catches the target
protein. The conjugated target antigenantibody complexes migrate by capillary action through a nitrocellulose membrane and
react with a specific fixed antibody on the
test line. The test includes a build-in control
to test the validity of the reagents and performance (108). Adopting straightforward,
rapid antigen detection is a trade-off for testing accuracy. Variable sensitivity of the RDT
compared to NAAT in samples from the upper respiratory tract has been observed and
ranges from 0-94%. However, the specificity
is consistently reported to be comparable
(108-112). The fluctuating viral load explains
the RDT's lower sensitivity during infection;
the test performs best during the symptomatic
and early stages of infection when the viral
load is high. Besides, the sample type, the
targeted antigen, and the testing quality influence the testing sensitivity (108, 113).
Indirect testing for current and/or previous SARS-CoV-2 infections could also be
performed to detect the immunological response to the infection. Nonetheless, serological testing is not recommended to diagnose
the infection since the appearance of a detectable level of immunoglobins does not
commonly occur in the early phase of SARSCoV-2 infection. It is observed that the serological assay sensitivity is as low as 30% in
the first week among symptomatic patients
and increases to around 90% in the third
week. Subsequently, a considerable proportion of contagious patients will be missed;
thus, the application of infection control and
medical intervention will be out of control.
Moreover, false-positive results are observed
in 2% of non-infected individuals, attributed
to cross-reactivity with other immunoglobulins such as SARS-CoV antibodies (114116).
Radiological examination
Imaging techniques are a powerful tool
in COVID-19 diagnosis. Typical chest Computed Tomography (CT) imaging features,
including patchy bilateral areas of groundglass infiltration that vary depending on the
disease stage, were observed in COVID-19
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pneumonia (117). The initial CT sensitivity
was more than 97% in a retrospective analysis, compared with around 85% for initial
qRT-PCR (118). However, CT risks crosscontamination between radiology personnel
and patients if proper precautions are not applied, aside from exposure to ionizing radiation (119). Although a chest X-ray is helpful
for COVID-19 diagnosis, it has low sensitivity, especially in early infections, even though
it could help assess disease progression
(119).

for COVID-19 under investigation in clinical
trials, and at least 75 trials are still in the preclinical stage (122). The vaccines are clustered into one of the six platforms: live attenuated viruses, recombinant viral vectors, inactivated viruses, protein subunits, virus-like
particles, and nucleic acid-based (124). Although using live, attenuated, and inactivated
viruses provides a high level of immunogenicity, it may pose safety concerns due to dealing with a whole virus or manufacturing error
(125).

VACCINES

The leading vaccine authorized by the
US Food and Drug Administration (FDA) is
BNT162b2, manufactured by New Yorkbased Pfizer and the German company BioNTech. The vaccine is named "Comirnaty"
(brand name) or "Tozinameran" (generic
name). It is composed of a modified RNA
that encodes the SARS-CoV-2 spike protein
(126). Even though the vaccine efficacy is
approximately 95%, it is approved in some
countries while others are on the emergency
use list (122). The second FDA-authorized
vaccine is Moderna's mRNA-1273 vaccine,
an mRNA vaccine made by the Boston-based
company Moderna and distributed for emergency use in many countries (122).

In typical situations, several years are
required to develop a safe and effective vaccine until released. A vaccine will pass
through preclinical testing and be followed
by three clinical development stages (120).
The preclinical stage is carried out in vitro
using cell culture, followed by in vivo experiments using animal models to confirm the
presence of immune response as a prerequisite for starting clinical trials on human subjects, which requires formal regulatory approval and ethical clearance. The vaccinebased clinical trials involve three subsequent
steps: phase I trials that primarily involve
safety and dosage testing in a small number
of people; phase II trials are carried out to
test the vaccine immunogenicity in an expanded population (several hundred) where
the subjects can be divided into groups in
order to observe any variation in response;
and phase III trials involve giving the vaccine
to a large number of people (several thousand) besides a placebo group to obtain
enough data regarding the vaccine efficacy
(121, 122).
An essential issue in vaccine development is the targeted antigen that should generate memory immune cell responses, so a
conserved structure in the pathogen should be
selected to overcome the process of immunological escape due to evolution (123). As the
S protein is pivotal in the virus life cycle, the
primary target in most vaccines for COVID19 is the S protein, except for the vaccine
platforms where the whole virion is used,
such as the live-attenuated and inactivated
viral vaccines (63). As of August 9, 2021, 19
vaccines gained either approval or limited
approval, but there are around 99 vaccines

Future prospective
Proper diagnosis and control of the recent outbreak is a challenging target globally.
As the SARS-Cov2 virus is rapidly overwhelming worldwide due to its high transmissibility and evolution, it is critical to keep
the applied diagnostic strategies in pace with
viral evolution to maintain control over the
diagnostic accuracy. Furthermore, ongoing
vaccine development and use should be accompanied by ongoing monitoring of sustained immune response's significance,
drawbacks, and efficacy. The recovered
COVID-19 patients must be tracked for any
potential long-lasting or late-developed signs
and symptoms with an incessant comparison
between the natural and vaccine-induced
immune responses.
CONCLUSION
This review concludes the key molecular
findings of the SARS-CoV-2, the third coronavirus causing a global pandemic. The advances in molecular methods make explicit
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remarks about the viral genome sequence,
which encodes for 16 non-structural proteins,
four structural proteins (S, M, E, and N), and
several accessory proteins. Several diagnostic
strategies have been developed since the beginning of the pandemic. However, the
NAAT has become the gold standard in
SARS-CoV-2 worldwide. The high evolution
of the viral genome is a potential threat to the
ongoing vaccine development projects and
the adopted diagnostic techniques. The ongoing cooperation in viral genome sharing, mutation reporting, and vaccine application outcomes, along with the clear understanding of
the viral lifecycle and pathogenicity, represents landmark progress in the pandemic.
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